DD - DuPont de Nemours, Inc.
64.00 +0.41 (0.64%)
Pre-Market: 9:16AM EST
| Previous Close | 61.99 |
| Open | 62.75 |
| Bid | 64.00 x 800 |
| Ask | 64.42 x 1000 |
| Day's Range | 62.75 - 63.95 |
| 52 Week Range | 17.84 - 85.50 |
| Volume | 6,531,915 |
| Avg. Volume | 4,078,995 |
| Market Cap | 47.108B |
| Beta (3Y Monthly) | 1.03 |
| PE Ratio (TTM) | 60.39 |
| EPS (TTM) | 1.05 |
| Earnings Date | Jan 29, 2020 - Feb 3, 2020 |
| Forward Dividend & Yield | 1.20 (1.89%) |
| Ex-Dividend Date | 2019-11-27 |
| 1y Target Est | 81.00 |
- Barrons.com
3M Stock Gets a Thumbs Down Because of Worry Over Environmental Liabilities
2019 was already a horrible, no-good, very bad year for the industrial conglomerate (MMM) Citigroup analyst Andrew Kaplowitz added a bit more unfavorable news, downgrading the stock to Hold from the equivalent of Buy because of uncertainty over 3M’s environmental liabilities. 3M (ticker: MMM) is setting aside money to clean up sites that produced a group of chemicals—referred to as PFAS—that can now be found in drinking water around the places where the chemicals were manufactured. “We simply see little in the way of near-term catalysts that could drive [3M] back to its historical [valuation] premium until more certainty relative to [the company’s] PFAS-related liability emerges,” wrote Kaplowitz in a Monday research report.
- Bloomberg
IFF Vies With Kerry in Deal for DuPont Nutrition Business
(Bloomberg) -- International Flavors & Fragrances Inc. has emerged as a strong contender to purchase DuPont Inc.’s nutrition division, challenging Ireland’s Kerry Group for the $25 billion asset, according to people with knowledge of the matter.IFF and Kerry are both negotiating with DuPont and the winner could reach a deal by year-end, the people said, asking not to be identified as the discussions are private. The transaction will create a new company comprised of the bidder’s assets and DuPont’s nutrition business that will be spun off to existing investors, the people said.DuPont shareholders will emerge from the so-called Reverse Morris Trust with a significant stake in the business, the people said. The new company aims to have an investment-grade credit rating and its board will include directors from DuPont and the bidder, the people said. The transaction is likely to take at least a year to close, they said.Representatives for DuPont, IFF and Kerry declined to comment. Discussions between the companies could still fall apart or Dupont could opt for a spinoff instead, the people said. IFF presents DuPont Chairman Ed Breen and Chief Executive Officer Marc Doyle with a distinct alternative to Kerry. While an RMT is easier between two U.S. companies, IFF’s $7.1 billion purchase of Frutarom Industries Ltd. last year is still absorbing management time and has increased leverage. In Kerry, they have an Irish company with deep roots in the dairy industry that’s keen to expand in food ingredients. Kerry trades at a higher earnings multiple than IFF, offering a potentially bigger valuation uplift to DuPont shareholders.DuPont opted for the most tax-efficient option to reward shareholders after the value of its nutrition business had wallowed below industry levels as part of a diversified company.The deal would be the biggest ever for IFF, which makes flavors and fragrances for food, beverages, personal care and household products. The company’s last big acquisition was in the food-flavoring industry last year, when it bought Israel’s Frutarom Industries Ltd. for $7.1 billion including debt.Kerry has long wanted to expand in healthy bacteria strains, ingredients found in dietary supplements, cheese and bakery products, and nutritional products that claim to have some sort of role in assisting in disease treatment or prevention. Kerry’s heritage lies in milk, cheese and other dairy products, and the company collects a billion liters of milk a year from small family farms in the southwest of Ireland.Shares of the company declined 0.2% to 116.30 euros as of 8:17 a.m. in Dublin.(Updates with Kerry share price in last paragraph.)\--With assistance from Andrew Noël and Ed Hammond.To contact the reporters on this story: Dinesh Nair in London at dnair5@bloomberg.net;Nabila Ahmed in New York at nahmed54@bloomberg.net;Kiel Porter in Chicago at kporter17@bloomberg.netTo contact the editors responsible for this story: Anthony Palazzo at apalazzo@bloomberg.net, Kevin MillerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Investopedia
10 Bargain Blue Chips with Improving Growth Prospects
Even as the market soars to new record highs, these stocks still have significant upside potential, per research by Bernstein.
- Investopedia
Profit Takers Abound as Stocks Pull Back
U.S. stock prices fell by 1%. The market anticipates more European growth, while gold and silver are poised to rally.
- GuruFocus.com
52-Week Company Lows
DuPont de Nemours, Exelon, Occidental Petroleum, Ventas, Plains All American Pipeline and CenterPoint Energy present buying opportunities Continue reading...
- Insider Monkey
Hedge Funds Warming Up To DuPont de Nemours, Inc. (DD)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- Bloomberg
What ‘Dark Waters’ Reveals About Corporate Science
(Bloomberg Opinion) -- A new movie, “Dark Waters,” shines a bright light on a group of dangerous chemicals that are likely in your bloodstream right now. It tells the true story of a polluter that manipulated research and kept evidence hidden from the public – and shows just how crucial it is that scientific evidence be produced by researchers free of conflicts of interest.The chemicals that drive the film’s drama, known as PFAS, are remarkably effective at repelling water and oil. They’re used to make familiar products such as Teflon, Scotchgard and Gore-Tex, and are found in the coating of pizza boxes and microwave-popcorn bags. Unfortunately, in recent years, they’ve also gained attention for their links to cancer, liver and thyroid disease, increased cholesterol, and depressed fertility. They’ve been found in the blood of almost every American ever tested, and they contaminate the water in communities across the U.S.“Dark Waters” focuses on how the chemical company DuPont manufactured Teflon in a West Virginia town, and in the process fouled the local drinking water with a PFAS compound. Over the course of the drama, viewers learn that DuPont hid much of what it knew about its effects. In 1981, for example, DuPont was informed by 3M (from which DuPont purchased much of its C8) that the chemical caused birth defects in rats; DuPont then learned of two apparent birth defects among children of its Teflon division employees. Both the PFAS-exposed babies and the rats were born with eye defects, making the link particularly alarming. But the firm never reported this in the scientific literature or revealed it to the public.When the first public concerns abound the compound emerged, DuPont did what too many corporations do: They took a page from Big Tobacco’s playbook and hired a firm to sow doubt about the scientific evidence. ChemRisk, whose top staff had consulted for cigarette manufacturers, produced a risk assessment with exactly the conclusion DuPont wanted: exposures around the plant were thousands of times lower than levels that cause illness.The film captures how a courageous attorney working virtually on his own was able to document DuPont’s coverup. Armed with those documents, the Environmental Protection Agency eventually issued its then largest-ever fine, and required DuPont to clean up the local water supply.Significantly, DuPont also agreed to fund a series of studies on C8’s effects on the plant’s workers and local residents. To ensure the research would be truly independent and credible, the two sides together selected scientists to direct the studies. The results were startling: C8 exposure increased the risk of testicular and kidney cancer, ulcerative colitis, thyroid disease, pregnancy-induced hypertension and elevated cholesterol. DuPont has since paid more than $600 million in compensation to thousands of people sickened with these conditions.As more studies document the wide range of toxic properties of PFAS compounds, manufacturers are rapidly eliminating the chemicals from their products, and lawmakers are eyeing legislation to clean up contaminated water systems. After hiring two product-defense consulting firms, Exponent and Gradient, to dispute the C8 studies, 3M settled a PFAS pollution claim made by the state of Minnesota for $850 million. But as the PFAS debacle has painfully made clear, the system through which scientific evidence is produced also needs to be cleaned up.First, corporations shouldn’t be allowed to sequester important scientific findings about the harms of their products. Stiff penalties could be applied when case reports of disease or the results of health-effects studies are not made public. The few corporations that get caught hiding data, like DuPont and 3M did, eventually pay large amounts to settle claims. But this is too late for people made sick or whose environment was damaged.Second, the public shouldn’t believe the results of studies done by product-defense consulting firms. After all, their business model is to provide clients with the ammunition to sway public opinion, slow regulation and defeat court claims. If they did otherwise, they would never be hired again.And finally, the model of scientific investigation highlighted in “Dark Waters” should be rule rather than the exception. To some extent, this is the model of the Health Effects Institute, a research organization that commissions research into the health effects of air pollution, set up and funded jointly by the Environmental Protection Agency and motor vehicle manufacturers. But for the most part, corporations have been reluctant to fund research over which they have no control.We badly need a new model for production of the evidence necessary to protect the public. When government agencies consider potentially harmful exposures and activities, from vaping to opioids to glyphosate to payday loans, they should insist the regulated industries provide data produced by unconflicted scientists. In this paradigm, the firms responsible for the potential harm would be required to pay for the research, but the studies would be conducted by scientists without conflicts of interest, under provisions that ensure their complete independence. Only then will we have confidence in the integrity of the results.To contact the author of this story: David Michaels atTo contact the editor responsible for this story: Tracy Walsh at twalsh67@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.David Michaels is a professor at the Milken Institute School of Public Health at George Washington University. He served as assistant secretary of labor for the Occupational Safety and Health Administration from 2009 to 2017, and is the author of the forthcoming book "The Triumph of Doubt: Dark Money and the Science of Deception."For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
- GuruFocus.com
Stocks That Fell to 3-Year Lows in the Week of Nov. 22
DuPont de Nemours, Simon Property Group, Expedia and Molson Coors Brewing present buying opportunities Continue reading...
- Simply Wall St.
Don't Race Out To Buy DuPont de Nemours, Inc. (NYSE:DD) Just Because It's Going Ex-Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
- PR Newswire
DuPont Recommends Rejection of TRC Capital's "Mini-Tender" Offer
WILMINGTON, Del., Nov. 21, 2019 /PRNewswire/ -- DuPont (DD) today announced that it has been notified of an unsolicited "mini-tender" offer by TRC Capital Investment Corporation to purchase up to 2 million shares, or approximately 0.27 percent of outstanding shares, of DuPont's common stock at $64.75 per share, which was approximately 4.27 percent below the closing share price of DuPont's common stock on Nov. 15, 2019 ($67.64), the last trading day prior to the date of TRC Capital's mini-tender offer, and approximately 0.46 percent below the closing share price of DuPont common stock on Nov. 20, 2019 ($65.05), the day prior to this release.
- Investopedia
Top Materials Stocks for December 2019
The materials sector includes companies engaged in the discovery, development, and processing of raw materials, which are used across many other sectors and industries. Materials stocks include manufacturers of products as varied as plastic, fertilizer, paper, concrete, metals, and more. Some prominent names in the materials sector include Dupont de Nemours Inc. (DD), Ecolab Inc. (ECL), and Dow Inc. (DOW).
- Bloomberg
DuPont Movie ‘Very Damaging,’ Analyst Says After Sneak Preview
(Bloomberg) -- The movie “Dark Waters” about the effect of deadly chemicals in West Virginia is “very damaging” for DuPont de Nemours Inc., Wall Street analysts at Fermium Research wrote in a report before its theatrical debut on November 22.Analyst Frank Mitsch -- who watched a sneak preview -- thinks that “Dark Waters” will probably be a hit film and may cast a shadow over DuPont shares and the entire chemical industry. The movie focuses on DuPont and Chemours Co.’s already-settled litigation over perfluorooctanoic acid production.DuPont’s shares fell as much as 2.7% on Friday in New York, while broader market inched higher.“We can see a scenario where interest in DD from individual investors (85% institutional ownership according to Bloomberg) dissipates, though also a broader concern for the chemicals sector given the negative portrayal,” he added.One positive, though, is that Chemours wasn’t mentioned at all during the movie, Mitsch said. The focus was solely on DuPont and it’s possible that the average moviegoer will likely “walk away disgusted” only with DuPont.For their part, investors are probably more interested in DuPont due to the prospect for merger and acquisition activity. The company has been exploring the divestiture of assets, Mitsch wrote, and if a deal occurs it’s possible that the negatives from the movie may subside.“Our hot-take is the film is a near-term negative, but when the first blockbuster M&A transaction gets announced, it may fade into the background,” the analyst concluded.To contact the reporter on this story: Aoyon Ashraf in Toronto at aashraf7@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Thomson Reuters StreetEvents
Edited Transcript of DD.N earnings conference call or presentation 31-Oct-19 12:00pm GMT
Q3 2019 Dupont De Nemours Inc Earnings Call
- Moody's
DuPont de Nemours, Inc. -- Moody's announces completion of a periodic review of ratings of DuPont de Nemours, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of DuPont de Nemours, Inc. New York, November 11, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of DuPont de Nemours, Inc. and other ratings that are associated with the same analytical unit. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
- Investopedia
7 Stocks Poised to Rise as Market Enters Best Stretch in 8 Decades
The November to January period historically offers the strongest stock market returns, and these stocks may be poised to ride that seasonal pattern.
- Zacks
Chemical Stock Earnings Due on Nov 7: APD, ESI, TROX & ICL
Let's take a look at how these chemical companies are poised ahead of their earnings release.
- Simply Wall St.
Should You Be Worried About DuPont de Nemours, Inc.'s (NYSE:DD) 7.4% Return On Equity?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- GuruFocus.com
US Indexes Close Higher Friday and for the Week
S&P; 500 up 22.19% for the year Continue reading...
- Barrons.com
It’s Been a Tough Year in Agriculture. Farm-Supply Stocks Take Different Paths.
Two companies that supply farmers— (CTVA) and (FMC)—are on different paths as investors assess their quarterly results. The stock (ticker: CTVA) fell 4% Thursday, worse than the 0.5% decline of the Dow Jones Industrial Average. For Corteva, “we had previously thought there was a possibility that domestic corn yields might be significantly impaired in 2019 due to adverse weather conditions that led to a very late planting season,” wrote Zekauskas in a Friday research report.
- Barrons.com
DuPont Stock ‘Is Too Cheap’ and Has Catalysts
DuPont stock is up a second straight day after reporting third-quarter numbers. Some on Wall Street see opportunity in the company’s nutrition business is sold or spun off.
- Investing.com
DuPont Rises 4%
Investing.com - DuPont (NYSE:DD) rose by 4.05% to trade at $68.57 by 10:31 (14:31 GMT) on Friday on the NYSE exchange.
- MarketWatch
DuPont says its nutrition & biosciences business got a boost from plant-based meat demand
One of the hottest food trends featured in the earnings of specialty chemicals company DuPont de Nemours Inc. on Thursday. The company said it's nutrition & biosciences (N&B) business saw a boost in food and beverage volumes driven by gains in specialty proteins from growing demand for plant-based meats. On the company's earnings call with analysts, Chief Operating Officer Marc Doyle said the company's plant-based meat business is "relatively small today," but that it is expected to grow in the double digits. Alternative meat has become a big business in the U.S., as companies' like Beyond Meat Inc. and Impossible Meat are introducing their products at more restaurants and fast-food outlets, as well as on grocery shelves. DuPont's N&B business is just one of four business segments, along with electronics & imaging, transportation & industrial and safety & construction. DuPont shares were up 1% Thursday, but have fallen 13% in 2019, while the S&P 500 has gained 21%.
- Zacks
DuPont (DD) Beats on Q3 Earnings & Sales, Narrows EPS View
DuPont (DD) gains from higher pricing, portfolio actions and cost control amid a challenging macroeconomic environment in Q3.
